Skip to Content

Charles River Laboratories International Inc CRL

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Charles River Reports Strong Q4 Results and Acquisition of Cognate BioServices; Raising FVE to $161

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Charles River announced fourth-quarter revenue of $791 million, ahead of our and FactSet’s consensus expectations, driven by 10.3% organic revenue growth and full-year revenue of $2.9 billion, growing 11.5% from the prior year. Full-year GAAP operating margin increased 140 basis points to 14.8% due to efforts to drive operating efficiency and temporary cost reductions related to COVID-19.

Read Full Analysis

Company Profile

Business Description

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.

Contact
251 Ballardvale Street
Wilmington, MA, 01887
T +1 781 222-6000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 18,400

Related